Theriva Biologics, Inc.
TOVX
$0.32
-$0.02-5.60%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.57M | 15.37M | 15.83M | 6.39M | 6.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.17M | 25.73M | 26.37M | 17.94M | 18.73M |
| Operating Income | -24.17M | -25.73M | -26.37M | -17.94M | -18.73M |
| Income Before Tax | -23.74M | -26.19M | -29.56M | -24.81M | -25.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.74 | -26.19 | -29.56 | -24.81 | -25.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.74M | -26.19M | -29.56M | -24.81M | -25.65M |
| EBIT | -24.17M | -25.73M | -26.37M | -17.94M | -18.73M |
| EBITDA | -24.07M | -25.62M | -26.26M | -17.81M | -18.59M |
| EPS Basic | -4.06 | -5.53 | -11.89 | -20.68 | -26.65 |
| Normalized Basic EPS | -2.48 | -3.37 | -5.49 | -7.93 | -11.48 |
| EPS Diluted | -4.06 | -5.53 | -11.89 | -20.68 | -26.65 |
| Normalized Diluted EPS | -2.48 | -3.37 | -5.49 | -7.93 | -11.48 |
| Average Basic Shares Outstanding | 48.49M | 22.00M | 13.46M | 7.49M | 5.39M |
| Average Diluted Shares Outstanding | 48.49M | 22.00M | 13.46M | 7.49M | 5.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |